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 Gastrointestinal stromal tumors are rare neoplasms developing from cells of Cajal in the gastrointestinal tract. The mainstay 
of such tumors treatment is surgery, whenever possible. The therapeutic management of inoperable and metastatic disease 
is based on tyrosine kinase inhibitors and imatinib is the main drug recommended for first line treatment. The introduction 
of imatinib and other inhibitors improved survival outcomes for this disease, but due to primary and secondary resistance 
there is still the urgent need for new medications. This paper presents the progress in the systemic therapy of GISTs based 
on the latest scientific data. The newly developed agents (ripretinib, avapritinib) meet the need to treat patients after the 
failure of previously available therapies and those with PDGFRA mutation D842V associated with resistance to imatinib. 
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Introduction
Gastrointestinal stromal tumors (GIST) develop from interstitial 
cells of Cajal in the gastrointestinal tract or their precursors. 
GISTs are rare neoplasms but are also the most common me-
senchymal tumors of the gastrointestinal tract. The incidence 
of GIST in most published studies is reported at 10–15 new 
cases/100,000 per year and it is reported as having increased 
during the last decades [1]. GISTs are most often located in the 
stomach (50–70%) and in the small bowel (30% in the jejunum 
or ileum, 5% in the duodenum) but less frequently they can 
be found in other parts of the gastrointestinal tract and also in 
the omentum, mesentery, peritoneum and pancreas [2, 3]. The 
median age at diagnosis is about 60–65 years [1, 3, 4]. Small 
GISTs usually remain asymptomatic but patients with larger 
tumors may have different symptoms depending on the loca-
tion of the tumor. Suspicion of possible GIST is usually based 
on imaging or endoscopic tests and should be confirmed with 
a pathology test including immunohistchemistry staining and 
molecular testing. GIST management should be implemented, 
especially in unresectable and metastatic cases, based on the 
decision of the multidisciplinary team who are experienced 
in soft tissue sarcomas.   
Diagnostics and molecular abnormalities
Suspicion of GIST is usually done based on imaging and endo-
scopic studies but this requires confirmation with pathology 
results. A biopsy is an important step in this diagnosis. There are 
2 typical histological patterns of GIST: a spindle cell (60–70% of 
cases) or epithelioid (30–40% of cases) character, or a combi-
nation of both in variable proportions [5]. GISTs stain positive 
for KIT (CD117) and DOG1. Almost all except about 5% of GISTs 
are immunohistochemically positive for CD117. These mino-
rity of cases refer mostly to GISTs with the PDGFRA mutation. 
DOG1 expression is almost exclusively characteristic for GIST 
and is independent of the KIT status. Immunohistochemistry 
is important to differentiate GISTs from other mesenchymal 
Warsaw Sacroma Meeting 
5th December 2020 
281
tumors. The differential diagnosis most often includes IHC 
staining with the following antibodies: CD34, SMA, h-calde-
smon, desmin, general cytokeratin or CK18, S100, HMB-45, and 
melan A. Three of the most important prognostic factors in 
GIST are: location (gastric GISTs have a better prognosis than 
the small bowel or rectal GISTs), size and mitotic activity. It is 
important to note that tumor rupture is an additional adverse 
prognostic factor. Risk assessment based on the mitotic count, 
tumor size and tumor location is important for therapeutic 
decisions as well choosing the follow-up procedures after 
radical treatment. High-risk patients generally reccure within 
1–3 years after the end of adjuvant therapy and low-risk pa-
tients may reccure later, but this is much less likely. This should 
be taken into consideration during follow-up procedures [6]. 
Mutational status is not included in any risk classification but 
has an important prognostic value and predictive significance 
for targeted therapies. GISTs with the PDGFR D842V muta-
tion are associated with imatinib resistance and KIT/PDGFRA 
wild type GISTs may have a special clinical presentation and 
course [6]. Mutations of the KIT gene are present in 80–85% 
of GIST cases. The most common mutation in sporadic GIST 
(approximately 60%) and the best response to imatinib is the 
mutation in exon 11 of the KIT gene. This mutation is also 
observed in the familial GIST. Mutation in exon 9 KIT is more 
common in GISTs originating from the small intestine and 
the colon; this mutation is related to a worse response to 
imatinib. Patients with a mutation in exon 9 of the KIT gene 
may benefit from a higher dose of imatinib i.e. 800 mg daily 
and from a sunitinib. Mutations in exon 13 and 17 KIT are very 
rarely present, those aberrations are described in the familial 
GIST and in such cases a response to imatinib was observed. 
PDGFRA gene mutations are present in 5–8% of GISTs. In the 
case of mutations in exon 12 and exon 14 of the PDGFRA gene, 
a clinical response to imatinib was observed. Most mutations 
in exon 18 of the PDGFRA gene are present in cases of tumors 
located in the stomach or the omentum; the D842V mutation 
is resistant to imatinib and sunitinib, while other types of 
PDGFRA mutations are sensitive to them. Wild-type GISTs, i.e. 
GISTs with no KIT or PDGRA mutations, constitute 12-15% of 
cases and are characterized by a poor response to imatinib 
and a better response to sunitinib. Such cases often include 
pediatric GISTs (as SDH-deficient), typically GISTs related to 
NF1 or Carney’s triad [3].
The system most often used for GIST staging is the Ame-
rican Joint Committee on Cancer (AJCC) TNM (TNM tumor/
node/metastasis) classification system with the latest update 
from 2018. 
Treatment
The treatment of GIST should be implemented, especially 
in unresectable cases, based on the experience of the GIST 
management multidisciplinary team and their decision. The 
therapeutic approach may include endoscopic resection 
(in the case of small asymptomatic lesions), surgery and 
medical therapy, and in some cases radiotherapy, chemo-
therapy, hepatic artery embolization, chemoembolisation 
of the hepatic artery branches, radiofrequency ablation and 
supportive care. 
Surgical treatment, if possible, remains the mainstay of GIST 
management. The main goal of surgery is an R0 resection (ne-
gative margins). The surgical approach depends on the tumor’s 
location and size, its adherence or invasion into adjacent struc-
tures and the patient’s general condition and comorbidities. 
In the case of smaller lesions, the laparoscopic approach can 
be considered but this needs to follow all rules for oncological 
surgery. It can be considered especially for GISTs located in 
the stomach. This procedure is clearly discouraged in patients 
with large tumors, because of the risk of tumor rupture, which 
is associated with a very high risk of relapse. Usually GISTs do 
not metastasize to the lymph nodes and consequently routine 
local lymph node dissection is not required unless suspected 
on imaging. Due to the high recurrence potential in each 
case of GIST, the possible use of adjuvant imatinib should be 
assessed based on the recurrence risk assessment. In case of 
R1 resection, it is recommended to assess the possibility to do 
secondary surgery (re-excision). It should be considered if there 
is a possibility to determine the location of the primary tumor 
and if the procedure is not related with serious consequences 
for the functioning of the gastrointestinal tract. In some cases 
resection R1 can be acceptable, for example, in cases when 
the resection R0 is associated with major functional sequalae 
and there is no response for preoperative systemic therapy, 
especially for low-risk lesions [4, 6].
Imatinib can be recommended in a preoperative setting 
until the maximum response is obtained, which usually ta-
kes 6–12 months from the beginning of treatment. During 
preoperative therapy the response has to be strictly assessed 
with imaging tests so as not to miss disease resistance and 
progression. The main indications for preoperative imatinib 
therapy are: a locally advanced tumor not eligible for a non-
-mutilating surgery like abdominoperineal excision, pelvic 
exenteration, negative margins (R0 resection) achievement can 
be problematic or the risk of perforation is high; preoperative 
treatment can allow for saving surgery like gastric wedge 
resection instead of gastrectomy, local excision instead of 
pancreatoduodenectomy [7]. Imatinib should be continued 
in an adjuvant setting for a total treatment duration of three 
years. The decision about implementation of adjuvant imati-
nib should be done based on a risk assessment. Based on the 
scale of Miettinen and Lasota (2006), which defines the risk 
assessment of GIST aggressiveness (frequency of metastases 
or cancer-related death) depending on the location, size, and 
mitotic activity, there are 6 prognostic groups defined. Ad-
juvant imatinib for 3 years should be used for patients with 
a high risk of relapse. 3-years therapy prolonged relapse-free 
survival (RFS) and overall survival (OS) in comparison to the 
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one-year treatment. The RFS was 65.6% vs. 47.9% for 36-month 
and 12-month imatinib therapy, respectively, and the five-year 
OS was 92% vs. 81.7%, respectively (NCT00116935) [8]. In 2020 
the updated data after a 10-year follow-up of this trial were 
presented and in the intent-to-treat cohorts for the 36-month 
group; the 5-year and 10-year OS rates were 92.0% and 79.0%, 
and in the 12-month group, 85.5% and 65.3%, respectively 
(HR 0.55, 95% CI 0.37–0.83; p = 0.004). It was concluded that 
about 50% of deaths can be avoided during the first decade 
of follow-up after surgery with the 3-year imatinib treatment 
as compared to the 1-year treatment [9]. Polish real-life data 
confirmed the efficacy of 3-year adjuvant therapy with ima-
tinib in patients with high-risk molecular profiled GIST. The 
authors found overrepresentation of exon 9 KIT mutants and 
ruptured tumors in a group of patients with disease relapses 
[10]. In addition to risk assessment, it is required to perform 
molecular tests to determine the status of the GIST mutation 
to avoid treatment of patients with low sensitivity or resistance 
to imatinib [11, 12].
Imatinib is the standard of care in the first line of unresec-
table/metastatic disease. The introduction of imatinib to the 
treatment of GIST was a crucial point in the management of 
this disease. Median overall survival in patients with advanced/
metastatic disease before imatinib was about 12–15 months. 
In cases of inoperable or metastatic disease, the treatment of 
choice is the use of imatinib, the tyrosine kinase inhibitor (TKI), 
in the standard dose of 400 mg per day, orally. The efficacy of 
imatinib in first line treatment of unresectable or metastatic 
GISTs was demonstrated in prospective clinical trials [13, 14]. 
Based on the long-term follow-up of patients treated in pro-
spective clinical trials, the median PFS was about 2–3 years 
and the median OS was about 5 years. The clinical benefit in 
prospective clinical trials was mostly due to partial responses 
(40%) and disease stabilization (36%); complete responses 
were rarely observed (5–7%). This efficacy has been confirmed 
in retrospective real-world studies [15, 16].
Primary and early resistance to imatinib during the first 6 
months of therapy is observed in about 10–15% of patients 
with GIST. In responders the acquired resistance may appear 
along with the duration of treatment. Approximately 40–50% 
of patients show signs of disease progression in 2–3 years of 
treatment with imatinib. Most often the acquired resistance 
results from a new mutation or additional mutations in the KIT 
or PDGFRA genes, leading to a conformation change of the 
receptor and the inability to bind to imatinib. 
In case of progression, it is recommended to increase the 
dose of imatinib to 800 mg daily, and in the case of lack of 
efficacy, to use sunitinib which is approved for second line 
treatment at an initial dose of 50 mg daily based on phase 
III study results (NCT00075218). The use of other TKIs, with 
different targets in the pathway can help overcome resistance 
to imatinib. They can also be used in the case of imatinib into-
lerance. Sunitinib is a multikinase inhibitor that targets PDGFR, 
KIT, VEGFR (vascular endothelial growth factor) and CSF-1R 
(colony stimulating factor 1 receptor). In a randomized phase 
III trial sunitinib was administered 50 mg orally once daily for 
4 weeks, followed by a 2-week period off. In this study the 
median PFS was 27 weeks in sunitinib group in comparison 
to 6 weeks in the placebo group [17–19]. In case of further 
progression or sunitinib intolerance, regorafenib and sorafenib 
are subsequent therapeutic options, although sorafenib is 
not approved for GIST treatment [20, 21]. Regorafenib, ano-
ther multikinase inhibitor targeting KIT, PDGFR, VEGFR, FGFR 
(fibroblast growth factor receptor) and RET, was registered in 
third-line treatment based on a phase III study named GRID 
(NCT01271712). In this study, regorafenib was dosed 160 mg 
daily every 3 out of 4 weeks. The patients treated with rego-
rafenib achieved median PFS of  4.8 months compared to 0.9 
months in the placebo group [22]. 
Taking into consideration the limited options of systemic 
therapy, re-challenge with previously tolerated and effective 
TKI for palliation of symptoms in case of PD, can be considered. 
The results of the randomized study published in 2013 indicate 
that rechallenge with imatinib can significantly improve PFS 
and DCR (the disease control rate) in patients with GIST after 
failure with at least imatinib and sunitinib, although the survival 
benefit was minimal [23]. 
Patients who progressed despite prior therapy or recurred 
should be considered for participation in clinical trials, if availa-
ble [24]. There are currently ongoing clinical trials with tyrosine 
kinase inhibitors of KIT and/or PDGFRA (sunitinib, regorafenib, 
crenolanib, ripretinib, avapritinib, cabozantinib, axitinib), immu-
notherapy (nivolumab and iplimumab, avelumab, pembroli-
zumab), tyrosine kinase inhibitors of MEK (binimetinib), mTOR 
inhibitor (temsirolimus) and other molecules [25]. Researchers 
from the Maria Sklodowska-Curie National Research Institute 
of Oncology, Warsaw, Poland, lead the clinical trial on the 
combination of axitinib with avelumab (AXAGIST) in imatinib 
and sunitinib refractory GIST (NCT04258956).
In patients with a preliminary inoperable disease, the 
resectability should be regularly assessed during treatment 
with imatinib and surgery should be done if at all possible. 
Similarly, in patients with oligometastatic disease, who expe-
rience response and subsequent stabilization of the lesions 
in two subsequent imaging tests done within 4–6 months, 
resection may be considered with the assumption of con-
tinuation of systemic therapy after surgery. This approach 
can improve progression-free survival and overall survival 
[26–28]. Surgical treatment is not appropriate for patients 
with multifocal progression during systemic therapy with 
imatinib or sunitinib. 
Recently approved systemic therapies
Recently, two new medications – avapritinib (BLU-285) and 
ripretinib (DCC-2618) – have been assessed in clinical trials in 
patients with GIST and included in GIST treatment in clinical 
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disease progression or discontinuation. Safety was assessed 
from the first dose of the study drug until 30 days after the 
last dose. The AEs were reported according to the National 
Cancer Institute Common Terminology Criteria for Adverse 
Events (NCI-CTCAE; version 4.03). 
The safety population included 82 patients, and the D842V 
population 56 patients. The median age was 62 years, 60% 
were men and 76% were white, in the safety population. 98% 
of patients had metastatic disease and 87% of patients were 
previously treated with at least one TKI. The median follow-up 
of patients in the safety population was 19.1 months. In the 
dose-expansion part of the study, the MTD 400 mg from the 
dose-escalation part was used. The higher incidence of grade 
3 cognitive adverse events (AEs) was observed during the early 
expansion part of the study and further dose reductions with 
the 400 mg starting dose after multiple cycles of treatment. 
The dose was subsequently reduced to 300 mg and eventually 
recommended for the second part of the study. Most treat-
ment-related adverse events (TRAEs) were grade G1–G2. At the 
400 mg dose, the most commonly reported TRAEs G1–G2 were 
nausea (in 71% of patients), periorbital edema (47%), fatigue 
(47%) and vomiting (47%). At the 300 mg dose, the most com-
mon TRAEs G1-G2 were nausea (in 69% of patients), diarrhea 
(41%), fatigue (38%) and decreased appetite (38%). TRAEs 
G3–G4 regardless of the dose, occurred in 57% of patients and 
the most commonly reported was anemia (in 17% of patients). 
Drug-related serious AEs of any grade were reported in 26% of 
patients. The most commonly observed were anemia (4% of 
patients), pleural effusion (4%), vertigo (2%) and diarrhea (2%). 
No treatment-related deaths were reported. There were 2 ca-
tegories of AEs of special interest (AESI) determined: cognitive 
effects and intracranial bleeding. The first category, cognitive 
effects (any cause), occurred in 40% of patients and included 
memory impairment (30%), cognitive disorder (10%), confusio-
nal state (9%), and encephalopathy (2%). Cognitive effects were 
mostly G1 (23%) and resulted in treatment discontinuation in 
2% of patients. Intracranial bleeding occurred in 2 patients 
(2%) and both AEs were G3, reported as possibly related to 
the study drug. 84% of patients required at least one dose 
reduction or treatment interruption. In the safety population, 
54% of patients discontinued treatment, mostly due to disease 
progression (32%) and AEs (18%). 11 deaths were reported 
but there were no treatment-related deaths. In the D842V 
population 34% of patients discontinued treatment, mostly 
due to disease progression (7%) and AEs (21%). 
The efficacy results for patients with PDGFRA D842V-mu-
tation GISTs treated with the approved dose of avapritinib are 
summarized in table I. 
In the patients with PDGFRA D842V-mutation GISTs treated 
at any dose level, confirmed overall responses (according 
to mRECIST v. 1.1, central review) were reported in 88% of 
patients (complete response, CR, in 9%; partial response, PR, 
in 79%; and disease stabilization, SD, in 13%). PFS at 3 months 
practice. The new medications meet the need to treat patients 
after the failure of previously available therapies and those 
with a PDGFRA mutation D842V associated with resistance 
to imatinib. 
Avapritinib is approved in Europe in monotherapy for the 
treatment of adult patients with unresectable or metastatic 
GIST harboring the platelet-derived growth factor receptor 
alpha (PDGFRA) D842V mutation [29]. In the US, the drug is 
approved for the treatment of adults with unresectable or 
metastatic gastrointestinal stromal tumors (GIST) harboring 
a platelet-derived growth factor receptor alpha (PDGFRA) exon 
18 mutation, including the PDGFRA D842V mutations [30].
Avapritinib is a Type 1 kinase inhibitor which demonstrated 
in vitro activity on the PDGFRA D842V and KIT D816V mutants 
associated with resistance to imatinib, sunitinib and regorafe-
nib. The drug demonstrated greater potency against clinically 
relevant KIT exon 11 and KIT exon 17 mutants than against 
the KIT wild-type [29, 31]. Avapritinib’s safety, tolerability and 
anti-tumor activity were assessed in patients with advanced 
GIST in the NAVIGATOR study (NCT02508532) [32]. This was an 
open-label, phase I study, which consisted of dose-escalation 
and dose-expansion parts. The study was done over 17 sites 
in 9 countries. Patients with unresectable GISTs were enrolled 
into the dose-escalation part of the study (n = 46, among 
them 20 patients with a PDGFRA D842V-mutant GIST). The 
dose-expansion part of the study included patients with an 
unresectable PDGFRA D842V-mutant GISTs (n = 36) regardless 
of previous treatment and patients with GISTs with other mu-
tations whose disease either progressed on imatinib alone or 
on imatinib along with at least one other TKI. Adult patients (at 
least 18 years old), with an ECOG (Eastern Cooperative Onco-
logy Group) PS 0–2 (performance status), and with adequate 
organ function were eligible. Avapritinib was administered 
orally, once daily in the dose-escalation part, starting with 
a dose of 30 mg, in 28-day cycles. Treatment was continued 
until unacceptable toxicity, noncompliance, withdrawal of 
consent, physician decision, disease progression, death, or the 
closure of the study. Primary endpoints were MTD (maximum 
tolerated dose), the dose recommended for part 2, safety, and 
overall response in the dose-expansion part. Safety was asses-
sed in all patients from the dose-escalation part and all patients 
with the PDGFRA D842V-mutant GIST from the dose-expansion 
part. The secondary endpoints were pharmacokinetics, the 
clinical benefit rate, the duration of the response, and PFS per 
mRECIST 1.1. The pre-specified exploratory endpoint was OS 
(overall survival). The activity was assessed in all patients with 
PDGFRA D842V-mutant GIST who received avapritinib and who 
had at least one target lesion and at least one post-baseline 
disease assessment by central radiology. The efficacy was as-
sessed based on mRECIST 1.1. (modified Response Evaluation 
Criteria in Solid Tumors, version 1.1). Response assessment 
was done using CT or MRI at screening, on day 1 of cycle 3, 
every 2 cycles up to cycle 13, and then every 3 months until 
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was 100% (95% CI 100–100), at 6 months 94% (88–100), and 
at 12 months 81% (69–93). The estimated OS at 6 months was 
100% (95% CI 100–100), at 12 months 91% (83–100), and at 
24 months 81% (67–94). 
The updated long-term data with the median follow-up of 
26 months from the phase I study NAVIGATOR were presented 
in 2020 during the annual ESMO (European Society for Medical 
Oncology Conference) [33]. The ORR among 38 patients with 
PDGFRA D842V-mutant GIST treated with avapritinib at a dose 
300/400 mg was 95% (CR in 13%, PR in 82%). The median du-
ration of response was 22 months, median PFS was 24 months 
and median OS was not reached. The PFS and OS rates at 36 
months were 34% and 71%, respectively. 21% of patients 
discontinued treatment due to treatment related AEs. No tre-
atment-related deaths were reported. The most common AEs 
in 10% of patients with PDGFRA D842V-mutant GIST treated at 
a dose of 300/400 mg were nausea, anemia, diarrhea, fatigue, 
memory impairment, periorbital edema, decreased appetite, 
increased lacrimation, abdominal pain, vomiting, peripheral 
edema, hypokalemia and increased bilirubin. 
The results of another study, with the acronym VOYAGER, 
phase III, open-label, randomized study in patients with locally 
advanced unresectable or metastatic GIST of avapritinib ver-
sus regorafenib in patients previously treated with imatinib 
and 1 or 2 other TKIs (NCT03465722) were announced by the 
study sponsor in April, 2020 [34, 35]. In this study the patients 
were randomized in 1:1 ratio to treatment with avapritinib at 
a dose of 300 mg daily (n = 240) or regorafenib at a dose of 
160 mg per day for 3 weeks out of every 4 weeks (n = 236). The 
primary endpoint was PFS determined by central radiological 
assessment per mRECIST v. 1.1. The reported median PFS for the 
avapritinib group was 4.2 months in comparison to 5.6 months 
in the regorafenib group. The difference between the arms 
was not statistically significant. The overall response rate (ORR) 
was 17% with avapritinib versus 7% for the regorafenib group. 
The secondary end point of the study included ORR (overall 
response rate), OS and quality of life.
Ripretinib is approved in the US by the FDA for the treat-
ment of adult patients with advanced gastrointestinal stromal 
tumors (GIST) who have received prior treatment with 3 or 
more kinase inhibitors, including imatinib [36]. The drug has 
not yet been authorized in Europe. 
Ripretinib is a switch-control multikinase inhibitor that 
broadly inhibits KIT and PDGFRA kinases, including activity 
for wild-type KIT and PDGFRA mutations and multiple prima-
ry and secondary mutations associated with drug-resistant 
GISTs. Ripretinib demonstrates a dual mechanism of action 
and specifically and durably binds to both the switch pocket 
and the activation loop to lock the kinase in an inactive state. 
In this way the molecule prevents downstream signalling and 
cell proliferation. In vitro ripretinib inhibited PDGFRB (platelet 
derived growth factor receptor β), TIE-2 (angiopoietin-1 recep-
tor), VEGFR2 (vascular endothelial growth factor receptor 2), 
and BRAF (serine and threonine-protein kinase B-raf ), among 
others [36–38]. A first-in-human phase I study (NCT02571036) 
in patients with GISTs and other advanced solid tumors deter-
mined the recommended phase II dose of ripretinib as 150 mg, 
once daily. This phase I study included expansion cohorts to 
assess the clinical benefit in 2 and 3 line treatment in patients 
with GIST. 150 patients with GIST were enrolled into the stu-
dy and received the ripretinib dose of at least 100 mg daily. 
Among them 141 had KIT mutations, 8 had PDGFRA mutations 
and 1 patient had SDH-deficient GIST. 114 GIST patients were 
treated at the dose of 150 mg daily. The patients were previo-
usly treated with other TKIs, 19 patients with previous 1 line, 
27 with 2 lines and 68 patients with at least 3 lines. The ORR 
among patients treated with the dose of 150 mg was 14%, the 
median PF was 24 weeks and for the patients treated in 2. or 
3. line, the ORR was 22% and median PFS was 36 weeks. G3–G4 
AEs reported by patients treated at the dose of 150 mg daily 
were asymptomatic lipase increases, anemia, blood bilirubin 
increased, hypertension, diarrhea, abdominal pain, back pain, 
hyperkalemia, hyponatremia, hypophosphatemia [39].
Ripretinib was then assessed in the INVICTUS study 
(NCT03353753) (tab. II). It was a double-blind, randomized, 
placebo-controlled phase III study in patients with previously 
treated, advanced GISTs. This study was done in 29 sites in 12 
countries. Adult patients (at least 18 years old) with advanced 
GISTs with progression on at least imatinib, sunitinib and rego-
rafenib or documented intolerance to any of these medications 
despite dose modifications with an ECOG PS 0–2 as well as 
adequate organ and bone marrow function were eligible 
for the study. The patients were randomly assigned in a ratio 
2:1 to receive either oral ripretinib 150 mg or placebo, once 
daily for 28-day cycles. The patients were treated until disease 
progression, unacceptable toxicity, or consent withdrawal. The 
patients assigned to the placebo arm were allowed to cross 
over to ripretinib 150 mg at the time of progression. Rando-
mization stratification was done according to the number of 
previous therapies and ECOG PS. The efficacy was assessed 
using mRECIST v. 1.1. Tumor assessments were done using CT 
scans at screening, then every cycle (for 4 weeks) up to cycle 
4. After cycle 4 assessments were continued every other cycle. 
In patients who crossed over from placebo to the ripretinib 
arm, tumor assessments were done every other cycle and at 
Table I. The best confirmed response by central assessment per mRECIST v. 
1.1 in patients with PDGFRA D842V-mutant GISTs in the group treated with 
avapritinib with a registered dose of 300 mg per day (n = 28) [32]
complete response 1 (4%)
partial response 25 (89%)
stable disease 2 (7%)
disease progression 0 (0%)
overall response 26 (93%; 95% CI 77–99)
clinical benefit 28 (100%; 95% CI 88–100)
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the end of treatment. During the double-blind period, tumor 
assessments were done on the basis of BICR (blinded indepen-
dent central review). Safety was assessed continuously from 
the signing of the informed consent until 30 days after the last 
dose of the study treatment. AEs were graded according to 
NCI-CTCAE v. 4.03. The primary endpoint was PFS, assessed by 
BICR. The key secondary efficacy endpoint was ORR and other 
secondary endpoints included OS, time to progression, time 
to best response, PFS by investigator assessment, QOL (quality 
of life), safety, disease control rate at 12 weeks and pharma-
cokinetic/pharmacodynamic analyses. The primary analysis 
was done in the intention-to-treat population (ITT). ITT was 
defined as all patients who signed informed consent and were 
randomized. Safety was assessed in patients who received at 
least one dose of the study drug. 154 patients were assessed 
for eligibility. 129 patients were randomly assigned to either 
the ripretinib group (n = 85) or the placebo group (n = 44). 
The median follow-up in the ripretinib group was 6.3 months 
and in the placebo arm it was 1.6 months. The relative dose 
intensity in the double-blind period was 100% in the ripretinib 
arm and 97% in the placebo arm. 15 patients did not cross over 
from the placebo group to the ripretinib group. Median PFS 
by BICR was 6.3 months (95% CI 4.6–6.9) in ripretinib group 
versus 1.0 month (0.9–1.7) in the placebo group (HR 0.15, 95% 
CI 0.09–0.25; p < 0.0001). Median PFS based on investigator 
assessment was 4.7 months (95% CI 4.2–8.2) in the ripretinib 
group and 1.0 months (0.9–1.4) in the placebo group (HR 
0.19, 95% CI 0.12–0.32). PFS at 6 months was estimated to be 
51% for the ripretinib arm and 3.2% for the placebo arm. The 
median time to progression was 6.4 months (95% CI 4.6–8.4) 
in the ripretinib group and 1.0 month (0.9–1.7) in the placebo 
group. Median OS was 15.1 months (95% CI 12.3–15.1) in the 
ripretinib group and 6.6 months (4.1–11.6) in the placebo 
group (HR 0.36, 95% CI 0.21–0.62). At 6 months, estimated OS 
at 6 months was 84.3% for the ripretinib arm and 55.9% for 
the placebo arm; 12 months estimated OS was 65.4% for the 
ripretinib arm and 25.9% for the placebo arm. 
The most common TRAEs (reported in ≥20% of patients 
in the ripretinib group) in patients receiving ripretinib were 
alopecia, fatigue, nausea, myalgia, palmar–plantar erythro-
dysesthesia and diarrhea. Palmar–plantar erythrodysesthesia 
was reported in patients treated with ripretinib only and all 
events were G1 (in 13% of patients) and G2 (8%). The most 
commonly reported G3–G4 TRAEs in the ripretinib group were 
lipase increase (in 5% of patients), hypertension (4%), fatigue 
(2%), and hypophosphataemia (2%). The most commonly re-
ported G3–G4 TRAEs in the placebo group were anaemia (7%), 
diarrhea (2%), fatigue (2%), dehydration (2%), hyperkalaemia 
(2%), decreased appetite (2%), acute kidney injury (2%), and 
pulmonary edema (2%). Treatment-related serious AEs were 
reported in 8 (9%) of the 85 patients treated with ripretinib and 
3 (7%) of the 43 patients receiving placebo. Treatment-related 
treatment-emergent AEs leading to a dose reduction were 
reported in 6% of patients in the group who received ripretinib 
and in 2% of the patients receiving placebo. Treatment-related 
treatment-emergent adverse events leading to study treat-
ment discontinuation were reported respectively in 5% and 
2% of patients. 1 treatment-related death was reported in the 
placebo and 1 in the ripretinib group. 
Role and physical functioning assessed by EORTC-QLQ-
-C30 as well overall health assessed by EQ-VAS were stable 
from the beginning to cycle 2 day 1 in the ripretinib group 
in comparison to decreases observed in the placebo group 
indicating a clinically relevant difference between ripretinib 
and the placebo [38].
Conclusions
GISTs are rare diseases and treatment should be based on 
multidisciplinary team decisions. This approach is especially im-
portant for unresectable tumors. The diagnosis must be based 
on imaging and endoscopic tests, and should be confirmed 
with pathology tests including IHC and molecular tests from 
the tissue from the biopsy. The main goal of GIST management 
is surgery with R0 resection. In some cases there is the need to 
administer preoperative therapy with imatinib with a careful 
follow-up during treatment with regards to the possibility of 
undergoing surgery. In high risk GISTs, perioperative imatinib 
therapy should be continued up to 3 years in total. In the case 
of a primarily operative GIST, risk assessment should be done 
and for high risk patients 3 years imatinib therapy should be 
implemented. For unresectable locally advanced or metastatic 
disease, systemic treatment with TKI should be started. The 
therapeutic options are limited and include imatinib, an incre-
ased dose of imatinib, sunitinib, regorafenib and sorafenib. For 
patients with mutations associated with resistance to imatinib, 
therapeutic options remain limited. 
Recently 2 new medicines – avapritinib and ripretinib – 
have been assessed in clinical trials in patients with GIST and 
Table II. The summary of efficacy results based on the INVICTUS study [36]
Ripretinib (n = 85) Placebo (n = 44) p value HR (95% CI)
PFSa (median, 95% CI) 6.3 (4.6, 6.9) 1.0 (0.9, 1.7) < 0.0001 0.15 (0.09, 0.25)
ORRa (%) (95% CI) 9 (4.2, 18) 0 (0, 8) 0.0504
OS (median, 95% CI) 15.1 (12.3, 15.1) 6.6 (4.1, 11.6) 0.36 (0.21, 0.62)
PFS – progression free survival; OS – overall survival; ORR – objective response rate; HR – hazard ratio; CI – confidence interval; a – assessed by BICR (blinded independent central 
review)
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implemented in clinical practice in GIST management. The 
new medications represent significant progress in patients 
after the failure of previously available therapies and those 
with a PDGFRA mutation D842V associated with resistance 
to imatinib. 
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